Esomeprazole strontium
Nexium Control (esomeprazole strontium) is a small molecule pharmaceutical. Esomeprazole strontium was first approved as Esomeprazole strontium on 2013-08-06. It is used to treat duodenal ulcer, esophagitis, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA. It has been approved in Europe to treat gastroesophageal reflux.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acid reducer | ANDA | 2025-03-04 |
| basic care esomeprazole magnesium | ANDA | 2024-07-25 |
| berkley and jensen heartburn treatment | ANDA | 2024-07-31 |
| careone esomeprazole magnesium | ANDA | 2019-12-18 |
| dg health esomeprazole magnesium | ANDA | 2024-08-02 |
| equaline esomeprazole magnesium | ANDA | 2024-08-01 |
| equate esomeprazole magnesium | ANDA | 2025-02-19 |
| esomeprazole | New Drug Application | 2025-01-09 |
| esomeprazole dr | ANDA | 2025-01-22 |
| esomeprazole magnesium | ANDA | 2025-03-11 |
Show 22 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BC: Proton pump inhibitors for peptic ulcer and gord
— A02BC05: Esomeprazole
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD06: Esomeprazole, amoxicillin and clarithromycin
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AE: Propionic acid derivatives, antiinflammatory and antirheumatic products
— M01AE52: Naproxen and esomeprazole
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Esomeprazole strontium |
| INN | esomeprazole |
| Description | Nexium Control (esomeprazole strontium) is a small molecule pharmaceutical. Esomeprazole strontium was first approved as Esomeprazole strontium on 2013-08-06. It is used to treat duodenal ulcer, esophagitis, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA. It has been approved in Europe to treat gastroesophageal reflux. |
| Classification | Small molecule |
| Drug class | antiulcer agents (benzimidazole derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.O.O.O.O.[Sr+2] |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2146140 |
| ChEBI ID | — |
| PubChem CID | 16048656 |
| DrugBank | — |
| UNII ID | N3PA6559FT (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Naproxen and esomeprazole magnesium, Vimovo
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use